{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T10:52:51Z","timestamp":1786272771738,"version":"build-2736575974"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.intimp.2024.112699","type":"journal-article","created":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T12:01:37Z","timestamp":1721217697000},"page":"112699","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Dihydroartemisinin ameliorates experimental autoimmune myasthenia gravis by regulating CD4+\u2009T cells and modulating gut microbiota"],"prefix":"10.1016","volume":"139","author":[{"given":"Yan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunan","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8537-8747","authenticated-orcid":false,"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4385-3591","authenticated-orcid":false,"given":"Yanbin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2024.112699_b0005","first-page":"14","article-title":"Clinical features of myasthenia gravis with neurological and systemic autoimmune diseases [J]","author":"Zhu","year":"2023","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112699_b0010","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3233\/JND-140045","article-title":"The epidemiology of neuromuscular disorders: a comprehensive overview of the literature [J]","volume":"2","author":"Deenen","year":"2015","journal-title":"Journal of Neuromuscular Diseases"},{"issue":"2","key":"10.1016\/j.intimp.2024.112699_b0015","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1212\/WNL.0b013e3181ad53c2","article-title":"Seropositive myasthenia gravis: a nationwide epidemiologic study [J]","volume":"73","author":"Heldal","year":"2009","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.intimp.2024.112699_b0020","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1159\/000529583","article-title":"Incidence, prevalence, hospitalization rates, and treatment patterns in myasthenia gravis: a 10-year real-world data analysis of german claims data [J]","volume":"57","author":"Wartmann","year":"2023","journal-title":"Neuroepidemiology"},{"issue":"1","key":"10.1016\/j.intimp.2024.112699_b0025","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/mus.27832","article-title":"Myasthenic crisis [J]","volume":"68","author":"Claytor","year":"2023","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.intimp.2024.112699_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102712","article-title":"Update in immunosuppressive therapy of myasthenia gravis [J]","volume":"20","author":"Lascano","year":"2021","journal-title":"Autoimmun Rev"},{"issue":"7","key":"10.1016\/j.intimp.2024.112699_b0035","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1136\/ard.2008.092163","article-title":"Dose-related patterns of glucocorticoid-induced side effects [J]","volume":"68","author":"Huscher","year":"2008","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.intimp.2024.112699_b0040","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/nyas.13567","article-title":"Gut microbiota and probiotics: novel immune system modulators in myasthenia gravis? [J]","volume":"1413","author":"Rinaldi","year":"2018","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.intimp.2024.112699_b0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2014.05.001","article-title":"Myasthenia Gravis: paradox versus paradigm in autoimmunity [J]","volume":"52","author":"Berrih-Aknin","year":"2014","journal-title":"J. Autoimmun."},{"issue":"2","key":"10.1016\/j.intimp.2024.112699_b0050","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/JS9.0000000000000164","article-title":"Myasthenia gravis in current status: epidemiology, types, etiology, pathophysiology, symptoms, diagnostic tests, prevention, treatment, and complications - correspondence [J]","volume":"109","author":"Rahman","year":"2023","journal-title":"International Journal of Surgery (london, England)"},{"issue":"1","key":"10.1016\/j.intimp.2024.112699_b0055","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1196\/annals.1405.042","article-title":"CD4+ T cells and cytokines in the pathogenesis of acquired myasthenia gravis [J]","volume":"1132","author":"Conti-Fine","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.intimp.2024.112699_b0060","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.clim.2019.05.006","article-title":"Inhibition of ROCK activity regulates the balance of Th1, Th17 and Treg cells in myasthenia gravis [J]","volume":"203","author":"Song","year":"2019","journal-title":"Clin. Immunol."},{"issue":"10","key":"10.1016\/j.intimp.2024.112699_b0065","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ni.2416","article-title":"Induction and molecular signature of pathogenic TH17 cells [J]","volume":"13","author":"Lee","year":"2012","journal-title":"Nat. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2024.112699_b0070","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41582-018-0110-z","article-title":"Immunotherapy in myasthenia gravis in the era of biologics [J]","volume":"15","author":"Dalakas","year":"2018","journal-title":"Nat. Rev. Neurol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112699_b0075","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.autrev.2015.09.005","article-title":"Thymoma associated with autoimmune diseases: 85 cases and literature review [J]","volume":"15","author":"Bernard","year":"2016","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.intimp.2024.112699_b0080","first-page":"11","article-title":"Differential gut microbiota and fecal metabolites related with the clinical subtypes of myasthenia gravis [J]","author":"Tan","year":"2020","journal-title":"Front. Microbiol."},{"issue":"7415","key":"10.1016\/j.intimp.2024.112699_b0085","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/nature11550","article-title":"Diversity, stability and resilience of the human gut microbiota [J]","volume":"489","author":"Lozupone","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2024.112699_b0090","first-page":"6","article-title":"The treg\/Th17 axis: a dynamic balance regulated by the gut microbiome [J]","author":"Omenetti","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.112699_b0095","first-page":"12","article-title":"Gut microbiota as regulators of Th17\/treg balance in patients with myasthenia gravis [J]","author":"Chen","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.112699_b0100","doi-asserted-by":"crossref","unstructured":"ZHENG P, LI Y, WU J, et al . Perturbed Microbial Ecology in Myasthenia Gravis: Evidence from the Gut Microbiome and Fecal Metabolome [J]. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2019, 6(18): 1901441. DOI: 10.1002\/advs.201901441.","DOI":"10.1002\/advs.201901441"},{"key":"10.1016\/j.intimp.2024.112699_b0105","doi-asserted-by":"crossref","first-page":"1337632","DOI":"10.3389\/fmicb.2024.1337632","article-title":"Gut microbiota and autoimmune neurologic disorders: a two-sample bidirectional Mendelian randomization study [J]","volume":"15","author":"Zhang","year":"2024","journal-title":"Front. Microbiol."},{"issue":"2","key":"10.1016\/j.intimp.2024.112699_b0110","doi-asserted-by":"crossref","first-page":"603","DOI":"10.7150\/ijbs.50364","article-title":"Dihydroartemisinin: a potential natural anticancer drug [J]","volume":"17","author":"Dai","year":"2021","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.intimp.2024.112699_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.103915","article-title":"Dihydroartemisinin ameliorates dextran sulfate sodium induced inflammatory bowel diseases in mice [J]","volume":"100","author":"Lei","year":"2020","journal-title":"Bioorg. Chem."},{"issue":"4","key":"10.1016\/j.intimp.2024.112699_b0120","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/1440-1681.13461","article-title":"Dihydroartemisinin attenuated the symptoms of mice model of systemic lupus erythematosus by restoring the Treg\/Th17 balance [J]","volume":"48","author":"Chen","year":"2021","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"issue":"9","key":"10.1016\/j.intimp.2024.112699_b0125","first-page":"526","article-title":"Therapeutic potential of artesunate in experimental autoimmune myasthenia gravis by upregulated T regulatory cells and regulation of Th1\/Th2 cytokines [J]","volume":"73","author":"Meng","year":"2018","journal-title":"Pharmazie"},{"issue":"3","key":"10.1016\/j.intimp.2024.112699_b0130","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.18632\/aging.203874","article-title":"Dihydroartemisinin attenuates pulmonary inflammation and fibrosis in rats by suppressing JAK2\/STAT3 signaling [J]","volume":"14","author":"You","year":"2022","journal-title":"Aging"},{"key":"10.1016\/j.intimp.2024.112699_b0135","article-title":"Dihydroartemisinin alleviates imiquimod-induced psoriasis-like skin lesion in mice involving modulation of IL-23\/Th17 axis [J]","volume":"12","author":"Liu","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2024.112699_b0140","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.neulet.2016.05.020","article-title":"Curcumin ameliorates experimental autoimmune myasthenia gravis by diverse immune cells [J]","volume":"626","author":"Wang","year":"2016","journal-title":"Neurosci. Lett."},{"issue":"5","key":"10.1016\/j.intimp.2024.112699_b0145","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/WCO.0000000000000596","article-title":"Myasthenia gravis: from autoantibodies to therapy [J]","volume":"31","author":"Mantegazza","year":"2018","journal-title":"Curr. Opin. Neurol."},{"issue":"21","key":"10.1016\/j.intimp.2024.112699_b0150","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.2174\/092986711796391633","article-title":"Low lymphocyte count and cardiovascular diseases [J]","volume":"18","author":"N\u00fa\u00f1EZ","year":"2011","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.intimp.2024.112699_b0155","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.3389\/fimmu.2017.01785","article-title":"Immunopathogenesis in myasthenia gravis and neuromyelitis optica [J]","volume":"8","author":"Wang","year":"2017","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.intimp.2024.112699_b0160","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/cei.13546","article-title":"Roles of cytokines and T cells in the pathogenesis of myasthenia gravis [J]","volume":"203","author":"Uzawa","year":"2021","journal-title":"Clin Exp Immunol"},{"issue":"1\u20132","key":"10.1016\/j.intimp.2024.112699_b0165","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jneuroim.2010.03.016","article-title":"Clinical implication of peripheral CD4+CD25+ regulatory T cells and Th17 cells in myasthenia gravis patients [J]","volume":"225","author":"Masuda","year":"2010","journal-title":"J. Neuroimmunol."},{"issue":"5","key":"10.1016\/j.intimp.2024.112699_b0170","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.immuni.2019.04.011","article-title":"T follicular helper cell biology: a decade of discovery and diseases [J]","volume":"50","author":"Crotty","year":"2019","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.intimp.2024.112699_b0175","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1212\/WNL.44.4.728","article-title":"Organ-specific autoantigens induce interferon-gamma and interleukin-4 mRNA expression in mononuclear cells in multiple sclerosis and myasthenia gravis [J]","volume":"44","author":"Link","year":"1994","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.intimp.2024.112699_b0180","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1365-3083.2012.02703.x","article-title":"T helper type 17 cells expand in patients with myasthenia-associated thymoma [J]","volume":"76","author":"Wang","year":"2012","journal-title":"Scand. J. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2024.112699_b0185","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s10875-012-9685-0","article-title":"Changes of Treg-associated molecules on CD4+CD25 +Treg cells in myasthenia gravis and effects of immunosuppressants [J]","volume":"32","author":"Xu","year":"2012","journal-title":"J. Clin. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2024.112699_b0190","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jaut.2005.01.013","article-title":"Myasthenia gravis patients with low plasma IL-6 and IFN-\u03b3 benefit from etanercept treatment [J]","volume":"24","author":"Tuzun","year":"2005","journal-title":"J. Autoimmun."},{"issue":"1pt2","key":"10.1016\/j.intimp.2024.112699_b0195","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2567.2009.03089.x","article-title":"Disequilibrium of T helper type 1, 2 and 17 cells and regulatory T cells during the development of experimental autoimmune myasthenia gravis [J]","volume":"128","author":"Mu","year":"2009","journal-title":"Immunology"},{"issue":"8","key":"10.1016\/j.intimp.2024.112699_b0200","article-title":"Primary B-cell deficiencies reveal a link between human IL-17-producing CD4 T-cell homeostasis and B-cell differentiation [J]","volume":"6","author":"Zimmer","year":"2011","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.intimp.2024.112699_b0205","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.cell.2015.11.009","article-title":"Single-Cell genomics unveils critical regulators of Th17 cell pathogenicity [J]","volume":"163","author":"Gaublomme jellert t, yosef n, lee y,","year":"2015","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.intimp.2024.112699_b0210","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nri.2017.50","article-title":"The dichotomous nature of T helper 17 cells [J]","volume":"17","author":"Stockinger","year":"2017","journal-title":"Nat. Rev. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2024.112699_b0215","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41422-020-0324-7","article-title":"Transcriptional and epigenetic basis of Treg cell development and function: its genetic anomalies or variations in autoimmune diseases [J]","volume":"30","author":"Ohkura","year":"2020","journal-title":"Cell Res."},{"issue":"1","key":"10.1016\/j.intimp.2024.112699_b0220","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1749-6632.2012.06840.x","article-title":"Functional defect in regulatory T cells in myasthenia gravis [J]","volume":"1274","author":"THIRUPPATHI","year":"2012","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.intimp.2024.112699_b0225","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.3389\/fmicb.2018.02627","article-title":"Altered gut microbiota in myasthenia gravis [J]","volume":"9","author":"Qiu","year":"2018","journal-title":"Front. Microbiol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112699_b0230","doi-asserted-by":"crossref","first-page":"14384","DOI":"10.1038\/s41598-018-32700-y","article-title":"Fecal microbiota profile in a group of myasthenia gravis patients [J]","volume":"8","author":"Moris","year":"2018","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.intimp.2024.112699_b0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e26030","article-title":"Curcumin protects mice with myasthenia gravis by regulating the gut microbiota, short-chain fatty acids, and the Th17\/Treg balance [J]","volume":"10","author":"Sun","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.intimp.2024.112699_b0240","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.803101","article-title":"Gut microbiota as regulators of Th17\/treg balance in patients with myasthenia gravis [J]","volume":"12","author":"Chen","year":"2021","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.intimp.2024.112699_b0245","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.smim.2013.10.009","article-title":"The plasticity of human Treg and Th17 cells and its role in autoimmunity [J]","volume":"25","author":"Kleinewietfeld","year":"2013","journal-title":"Semin. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2024.112699_b0250","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1053\/j.gastro.2010.12.002","article-title":"Characterization of interleukin-17-producing regulatory T cells in inflamed intestinal mucosa from patients with inflammatory bowel diseases [J]","volume":"140","author":"Hovhannisyan","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.intimp.2024.112699_b0255","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.neuroscience.2023.11.029","article-title":"Dihydroartemisinin protects mice from CUMS-induced depression-like behaviors by regulating gut microbes [J]","volume":"547","author":"Tang","year":"2024","journal-title":"Neuroscience"},{"issue":"5","key":"10.1016\/j.intimp.2024.112699_b0260","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1007\/s10787-021-00848-1","article-title":"Kaempferol potentiates the sensitivity of pancreatic cancer cells to erlotinib via inhibition of the PI3K\/AKT signaling pathway and epidermal growth factor receptor [J]","volume":"29","author":"Zhang","year":"2021","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.intimp.2024.112699_b0265","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41392-019-0079-0","article-title":"Targeting cell signaling in allergic asthma [J]","volume":"4","author":"Athari","year":"2019","journal-title":"Signal Transduct. Target. Ther."},{"issue":"14","key":"10.1016\/j.intimp.2024.112699_b0270","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20143525","article-title":"Defining bronchial asthma with phosphoinositide 3-kinase delta activation: towards endotype-driven management [J]","volume":"20","author":"Jeong","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.intimp.2024.112699_b0275","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1002\/ptr.7429","article-title":"Anti-inflammatory effect of Rhein on ulcerative colitis via inhibiting PI3K\/Akt\/mTOR signaling pathway and regulating gut microbiota [J]","volume":"36","author":"Dong","year":"2022","journal-title":"Phytotherapy Research : PTR"},{"key":"10.1016\/j.intimp.2024.112699_b0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109647","article-title":"Semaglutide, a novel glucagon-like peptide-1 agonist, amends experimental autoimmune encephalomyelitis-induced multiple sclerosis in mice: involvement of the PI3K\/Akt\/GSK-3\u03b2 pathway [J]","volume":"115","author":"Sadek","year":"2023","journal-title":"Int. Immunopharmacol."},{"issue":"2","key":"10.1016\/j.intimp.2024.112699_b0285","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1093\/ndt\/gfq496","article-title":"The PI3K\/Akt\/mTOR pathway is activated in murine lupus nephritis and downregulated by rapamycin [J]","volume":"26","author":"Stylianou","year":"2011","journal-title":"Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association"},{"issue":"4","key":"10.1016\/j.intimp.2024.112699_b0290","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s11011-020-00533-2","article-title":"Dihydroartemisinin ameliorates LPS-induced neuroinflammation by inhibiting the PI3K\/AKT pathway [J]","volume":"35","author":"Gao","year":"2020","journal-title":"Metab. Brain Dis."},{"key":"10.1016\/j.intimp.2024.112699_b0295","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.biopha.2018.03.142","article-title":"Effects of Artesunate on chondrocyte proliferation, apoptosis and autophagy through the PI3K\/AKT\/mTOR signaling pathway in rat models with rheumatoid arthritis [J]","volume":"102","author":"Feng","year":"2018","journal-title":"Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie"},{"key":"10.1016\/j.intimp.2024.112699_b0300","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.01134","article-title":"Network-based methods for prediction of drug-target interactions [J]","volume":"9","author":"Wu","year":"2018","journal-title":"Front. Pharmacol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924012207?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924012207?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T07:23:04Z","timestamp":1732951384000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924012207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":60,"alternative-id":["S1567576924012207"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112699","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dihydroartemisinin ameliorates experimental autoimmune myasthenia gravis by regulating CD4+\u2009T cells and modulating gut microbiota","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112699","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112699"}}